Literature DB >> 29772460

Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?

Michał Kunc1, Wojciech Biernat2, Elżbieta Senkus-Konefka3.   

Abstract

The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most important prognostic and predictive immunohistochemical markers in breast cancer. Breast cancers may express various profiles of hormone receptors: ER(+)/PgR(+), ER(-)/PgR(-), ER(+)/PgR(-) and ER(-)/PgR(+). The existence of the latter profile is a matter of controversy since PgR expressions is induced by ER-dependent pathways in breast cancer cells. One of the most extensively propagated hypotheses trying to explain the origin of ER(-)/PgR(+) breast cancers claims that they are technical artifacts dependent on the immunohistochemical procedure. On the other hand, in recent years there is a growing body of evidence, suggesting that such cancers create a unique group with distinct molecular and clinical features. In the following review, we present background theories on the ER(-)/PgR(+) breast cancer origin and their epidemiological and clinicopathological characteristics, including the predictive and prognostic significance of these rare tumors.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Estrogen receptor; Pathogenesis; Progesterone receptor; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 29772460     DOI: 10.1016/j.ctrv.2018.05.005

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  14 in total

1.  Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2.

Authors:  Yunxiao Xiao; Jiexiao Li; Zhenghao Wu; Ximeng Zhang; Jie Ming
Journal:  Gland Surg       Date:  2022-01

2.  The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.

Authors:  S Gamrani; S Boukansa; Z Benbrahim; N Mellas; F Fdili Alaoui; M A Melhouf; C Bouchikhi; A Banani; M Boubbou; T Bouhafa; H El Fatemi
Journal:  Breast J       Date:  2022-05-17       Impact factor: 2.269

3.  Is oestrogen receptor-negative/progesterone receptor-positive (ER-/PR+) a real pathological entity?

Authors:  Adedayo A Onitilo; Jessica Engel; Adedayo O Joseph; Ya-Huei Li
Journal:  Ecancermedicalscience       Date:  2021-08-24

Review 4.  Minireview: Parabens Exposure and Breast Cancer.

Authors:  Emily Hager; Jiangang Chen; Ling Zhao
Journal:  Int J Environ Res Public Health       Date:  2022-02-08       Impact factor: 4.614

5.  Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.

Authors:  Anna Diana; Francesca Carlino; Giuseppe Buono; Giuliano Antoniol; Vincenzo Famiglietti; Carmine De Angelis; Simone Carrano; Antonio Piccolo; Ferdinando De Vita; Fortunato Ciardiello; Bruno Daniele; Grazia Arpino; Michele Orditura
Journal:  Front Oncol       Date:  2022-03-28       Impact factor: 6.244

6.  Ultrasonic Omics Based on Intelligent Classification Algorithm in Hormone Receptor Expression and Efficacy Evaluation of Breast Cancer.

Authors:  Musu Ala; Jianlin Wu
Journal:  Comput Math Methods Med       Date:  2022-03-03       Impact factor: 2.238

7.  The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status.

Authors:  Hengqiang Zhao; Yiping Gong
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

8.  Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.

Authors:  Yunhai Li; Dejuan Yang; Xuedong Yin; Xiang Zhang; Jiefeng Huang; Yusheng Wu; Mengxue Wang; Zhiying Yi; Hongyuan Li; Hongzhong Li; Guosheng Ren
Journal:  JAMA Netw Open       Date:  2020-01-03

9.  Exploring the molecular targets and mechanisms of [10]-Gingerol for treating triple-negative breast cancer using bioinformatics approaches, molecular docking, and in vivo experiments.

Authors:  Ping Huang; Peijuan Zhou; Yuqi Liang; Jiahua Wu; Guosong Wu; Rui Xu; Yan Dai; Qianqian Guo; Hai Lu; Qianjun Chen
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

10.  Arrabidaea chica chloroform extract modulates estrogen and androgen receptors on luminal breast cancer cells.

Authors:  Douglas C Brandão; Paula M A P Lima; Isabella C Martins; Carina S Cordeiro; Antonielle O Cordeiro; Lara Vecchi; Joyce F C Guerra; Priscila C Orsolin; Matheus C Gazolla; Danilo S Costa; Ademar A da Silva Filho; Thaise G Araújo
Journal:  BMC Complement Med Ther       Date:  2022-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.